Balanced news tone
News Sentiment
COCP sentiment intelligence
Cocrystal Pharma Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
55
Balanced news tone
51 relevant articles
News tone and price action are not far from neutral.
82/100 classification confidence.
directly relevant articles
high-authority source matches
-2.9% over one week, +1.5% over four weeks, trend inactive, and below fair value.
What's Driving the Micro-Cap Mania in SKYQ and COCP
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
82/100 classification
One-week reaction
-2.9%
Price reacting lower
Trend fit
Trend inactive
1.5% over four weeks
Fair value
-38.8%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
12
Neutral
35
Negative
4
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
Kavout | AI
Direct company coverage
What's Driving the Micro-Cap Mania in SKYQ and COCP
This article examines the explosive premarket surges in micro-cap stocks Sky Quarry (SKYQ) and Cocrystal Pharma (COCP), driven by significant catalysts. SKYQ's rally is attributed to strategic Nevada refinery talks and rising Brent crude prices, despite its concerning financial h
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jul 2026 14:11
- Source
- Kavout | AI
TradingView
Direct company coverage
Price to book forward of Cocrystal Pharma Inc – FWB:8CC
This article provides financial information for Cocrystal Pharma Inc (FWB:8CC) on the Frankfurt Stock Exchange, specifically focusing on its "Price to book forward" metric. The content indicates that the market is closed with no trades and gives a general overview of the company'
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jul 2026 01:08
- Source
- TradingView
dars.gov.et
Direct company coverage
Cocrystal Pharma (COCP) Holds Near Key Support After Slight Decline - PCR Extreme
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 08 Jul 2026 16:34
- Source
- dars.gov.et
Finviz
Direct company coverage
COCP - Cocrystal Pharma Inc Dividends
This page provides a detailed financial overview of Cocrystal Pharma Inc (COCP), including its last close price, market capitalization, income, sales, and various financial ratios. It also lists dividend information (all showing as unavailable), performance metrics over different
- Tone
- Neutral 50/100
- Event
- Capital return
- Published
- 06 Jul 2026 00:40
- Source
- Finviz
DonanımHaber
Direct company coverage
Cocrystal Pharma (COCP) Inches Up as Stock Tests Key Resistance Levels - Diamond Pattern
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 07:00
- Source
- DonanımHaber
TradingView
Direct company coverage
Price to sales forward of Cocrystal Pharma, Inc. – NASDAQ:COCP
This page provides financial information for Cocrystal Pharma, Inc. (NASDAQ: COCP), specifically focusing on its forward price-to-sales ratio. It indicates that the company's market is currently closed with no trades. The content highlights the availability of financial data, new
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 09:10
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to revenue forward of Cocrystal Pharma, Inc. – NASDAQ:COCP
The article focuses on the enterprise value to revenue forward metric for Cocrystal Pharma, Inc. (NASDAQ:COCP). It appears to be a financial data point or analysis, although no specific numerical data is provided in the content. The layout suggests it's a page from a financial tr
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 22:39
- Source
- TradingView
TradingView
Direct company coverage
8CC Forecast — Price Target — Prediction for 2027
This article provides a forecast for Cocrystal Pharma Inc (8CC) stock, including analyst price targets, historical performance data, and financial metrics. It highlights that analysts have a max estimated price of 8.61 EUR and a min of 6.89 EUR for 8CC. The piece also covers curr
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 26 Jun 2026 21:09
- Source
- TradingView
TradingView
Direct company coverage
Price to book forward of Cocrystal Pharma Inc – LS:A3DWYX
The article provides information regarding the "Price to book forward" for Cocrystal Pharma Inc (LS:A3DWYX) on TradingView. It appears to be a financial data point for the company, accessible through the platform's financials section. The content primarily lists navigation and fo
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 12:10
- Source
- TradingView
TradingView
Direct company coverage
Cocrystal Pharma Inc Actuals & Estimates (NASDAQ:COCP)
The article provides actuals and estimates for Cocrystal Pharma, Inc. (COCP) stock, including historical price data, analyst forecasts, financial metrics, and company information. It details COCP's current price, market capitalization, earnings, revenue, and upcoming earnings rep
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 09:39
- Source
- TradingView
Moomoo
Direct company coverage
Cocrystal Pharma(COCP) Stock Options Chain | Quotes & News
This article provides access to the stock options chain, quotes, and news for Cocrystal Pharma (COCP). It serves as a resource for investors and analysts interested in detailed financial information and market performance related to the company.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 09:10
- Source
- Moomoo
TradingView
Direct company coverage
COCP Forecast — Price Target — Prediction for 2027
This article provides an overview of Cocrystal Pharma, Inc. (COCP) stock, including current price, historical performance, and analyst forecasts for 2027. It details analyst price targets, past earnings, revenue, and market capitalization, along with key financial dates like the
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 07:10
- Source
- TradingView
TradingKey
Direct company coverage
Cocrystal Pharma Inc (COCP) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Cocrystal Pharma Inc (COCP), featuring its current price momentum score, support and resistance levels, and a detailed breakdown of various technical indicators and moving averages. The analysis suggests the stock is suitable for rang
- Tone
- Negative 38/100
- Event
- Market update
- Published
- 22 Jun 2026 19:09
- Source
- TradingKey
TradingKey
Direct company coverage
Cocrystal Pharma Inc (COCP) Financial Health: Profitability & Balance Sheet Analysis
This article analyzes the financial health of Cocrystal Pharma Inc (COCP), noting its current financial score of 6.43, which ranks it 252 out of 389 in the Biotechnology & Medical Research industry. While its financial status is robust, its operating efficiency is low. The report
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2026 07:10
- Source
- TradingKey
TradingKey
Direct company coverage
Cocrystal Pharma Inc (COCP) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Cocrystal Pharma Inc (COCP), listing major individual and institutional holders and their respective proportions. It includes information on shareholder types, institutional shareholding trends over several quarters, and recent sh
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 09:40
- Source
- TradingKey
TradingKey
Direct company coverage
Cocrystal Pharma Inc (COCP) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides historical data on Cocrystal Pharma Inc (COCP) regarding its dividends and stock splits. It notes that the company has distributed no dividends over the past five years and details a series of 12-to-1 reverse merger stock splits that occurred on October 10,
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 18 Jun 2026 00:40
- Source
- TradingKey
TradingKey
Direct company coverage
Cocrystal Pharma Inc (COCP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey attempts to provide a revenue breakdown for Cocrystal Pharma Inc (COCP) by business segments and regional contributions. However, it explicitly states that relevant data for these breakdowns have not been disclosed by the company. The page displays cu
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 17 Jun 2026 19:40
- Source
- TradingKey
TradingKey
Direct company coverage
Cocrystal Pharma Inc (COCP) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Cocrystal Pharma Inc (COCP), highlighting its current earnings forecast score of 8.00 in the Biotechnology & Medical Research industry. Analysts have set an average price target of $8.00 with a "Buy" rating. The report also includes
- Tone
- Positive 63/100
- Event
- Earnings
- Published
- 17 Jun 2026 05:09
- Source
- TradingKey
Minichart
Direct company coverage
Cocrystal Pharma Appoints James Sapirstein as New CEO – Leadership Transition and Company Details
Cocrystal Pharma, Inc. has announced the appointment of James Sapirstein as its new Chief Executive Officer, detailed in a recent 8-K filing. The appointment emphasizes a transparent transition with no related party transactions and includes stock-based incentives for Sapirstein,
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 09 Jun 2026 15:10
- Source
- Minichart
Stock Titan
Direct company coverage
James Sapirstein becomes CEO of Cocrystal Pharma (NASDAQ: COCP)
Cocrystal Pharma, Inc. has appointed James Sapirstein as its new Chief Executive Officer, effective immediately. He will receive an annual salary of $265,000, a target bonus of 50% of his base salary, and stock options for 235,000 shares, with a potential for an additional 235,00
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 09 Jun 2026 11:10
- Source
- Stock Titan
Market source
Direct company coverage
Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer
Cocrystal Pharma Inc. has appointed James Sapirstein as its new Chief Executive Officer, effective immediately. Sapirstein brings extensive biopharma leadership and antiviral development experience, having led 23 product launches in his career. He replaces former Co-CEOs Sam Lee
- Tone
- Positive 74/100
- Event
- Market update
- Published
- 05 Jun 2026 02:09
- Source
- Market source
Moomoo
Direct company coverage
Cocrystal Pharma Appoints James Sapirstein as Chief Executive Officer
Cocrystal Pharma has appointed James Sapirstein as its new Chief Executive Officer. Sapirstein brings extensive experience in the pharmaceutical industry, and his leadership is expected to guide the company's strategic initiatives and growth. This appointment marks a significant
- Tone
- Positive 70/100
- Event
- Market update
- Published
- 04 Jun 2026 23:40
- Source
- Moomoo
www.marketscreener.com
Direct company coverage
Cocrystal Pharma Inc. Plans to Appoint James Sapirstein as A Member of the Board of Directors
Cocrystal Pharma Inc. announced its plan to appoint James Sapirstein to its Board of Directors. Sapirstein brings extensive pharmaceutical industry leadership, development, and business development experience, having led 23 product launches and held executive roles at Contravir P
- Tone
- Positive 77/100
- Event
- Market update
- Published
- 03 Jun 2026 23:10
- Source
- www.marketscreener.com
Stock Titan
Direct company coverage
Cocrystal Pharma (COCP) CEO awarded 235,000 stock options under 2025 plan
Cocrystal Pharma Inc.'s CEO, James Sapirstein, has been granted 235,000 stock options under the company's 2025 Equity Incentive Plan. These options have an exercise price of $1.12 per share and will vest in four equal annual installments starting June 3, 2027, with an expiration
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Jun 2026 19:41
- Source
- Stock Titan
Stock Titan
Direct company coverage
Cocrystal Pharma (COCP) CEO James Sapirstein files initial Form 3
Cocrystal Pharma's CEO, James Sapirstein, has filed an initial Form 3 with the SEC, establishing his status as an insider of the company. This filing is required for officers, directors, and large shareholders when they assume such roles, but it does not indicate any current stoc
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Jun 2026 19:41
- Source
- Stock Titan
Finviz
Direct company coverage
COCP - Cocrystal Pharma Inc Stock Price and Quote
This article provides a detailed stock quote and company overview for Cocrystal Pharma Inc (COCP), including financial data, performance metrics, and recent news releases. It also lists insider transactions by Director Phillip Frost. The company is a clinical-stage biotechnology
- Tone
- Positive 60/100
- Event
- Market update
- Published
- 03 Jun 2026 11:13
- Source
- Finviz
Stock Titan
Direct company coverage
Antiviral executive James Sapirstein takes helm at Cocrystal Pharma
Cocrystal Pharma (COCP) has appointed James Sapirstein as its new Chief Executive Officer, effective immediately, and plans to add him to the Board of Directors. Sapirstein brings extensive biopharma leadership and antiviral development experience, having participated in or led 2
- Tone
- Positive 72/100
- Event
- Market update
- Published
- 03 Jun 2026 10:41
- Source
- Stock Titan
GlobeNewswire
Direct company coverage
Cocrystal Pharma Appoints James Sapirstein, Biopharma
Cocrystal Pharma Inc. has appointed James Sapirstein as its new Chief Executive Officer, effective immediately. Mr. Sapirstein brings extensive biopharma industry leadership and antiviral development experience and will also join the company's Board of Directors. The previous Co-
- Tone
- Positive 71/100
- Event
- Market update
- Published
- 03 Jun 2026 10:41
- Source
- GlobeNewswire
Stock Titan
Direct company coverage
Veteran antiviral leader James Sapirstein to head Cocrystal Pharma (NASDAQ: COCP)
Cocrystal Pharma (NASDAQ: COCP) has appointed James Sapirstein as its new Chief Executive Officer, effective immediately. Sapirstein, who brings extensive experience in the biopharma industry and antiviral development, will also join the Board of Directors. Former Co-CEOs Sam Lee
- Tone
- Positive 69/100
- Event
- Market update
- Published
- 03 Jun 2026 10:41
- Source
- Stock Titan